[^1]
| Gene |
[ATXN7](/genes/atxn7) |
| UniProt |
O75376 |
| PDB |
No structures deposited |
| Mol. Weight |
95 kDa (892 aa); expanded mutant: up to 200+ kDa |
| Localization |
Nucleus (nuclear matrix, nucleolus) |
| Family |
Ataxin family, SCA7 proteins |
| Diseases |
[Spinocerebellar Ataxia Type 7 (SCA7)](/diseases/spinocerebellar-ataxia-type-7) |
Ataxin-7 is a nuclear protein encoded by the ATXN7 gene that functions as a component of the SPT3/SAGA/SLIK histone acetyltransferase (HAT) complex. In its wild-type form, ataxin-7 is involved in transcriptional regulation through chromatin remodeling. However, pathogenic expansions of a polyglutamine (polyQ) tract in the N-terminal region cause spinocerebellar ataxia type 7 (SCA7), a progressive neurodegenerative disorder characterized by cerebellar degeneration, retinal dystrophy, and systemic multi-system involvement.
Ataxin-7 is a 892-amino acid protein with the following domain organization:
- Polyglutamine (polyQ) tract (aa ~10-90): Normal: 7-35 glutamines; Pathogenic: 36-306 glutamines. The polyQ expansion causes protein misfolding and aggregation
- N-terminal region (aa 91-300): Contains the SCA7 disease domain and interaction sites
- SAGA interaction domain (aa 300-500): Binds to SPT3, SPT8, and other SAGA complex subunits
- C-terminal region (aa 501-892): Contains nuclear localization signals (NLS) and protein-protein interaction motifs
No crystal structures are available, but the AlphaFold model reveals the overall protein fold: AlphaFold Entry O75376.
Under physiological conditions, ataxin-7 performs essential functions:
Ataxin-7 is a stable component of the SAGA (Spt-Ada-Gcn5-Acetyltransferase) histone acetyltransferase complex, which regulates:
- Gene transcription through histone H3/H4 acetylation
- Chromatin remodeling
- RNA polymerase II recruitment
The SAGA-ataxin-7 module is particularly important for:
- Expression of photoreceptor-specific genes
- Cerebellar neuron gene regulation
- Cellular stress response genes
Ataxin-7 interacts with:
- SAGA complex subunits (SPT3, SPT8, SPT20, GCN5)
- Transcription factors
- Nuclear co-repressors
SCA7 is an autosomal dominant disorder caused by CAG trinucleotide repeat expansions in the ATXN7 gene. The expanded polyQ tract leads to:
-
Protein Aggregation
- Mutant ataxin-7 forms insoluble nuclear aggregates
- Aggregates sequester normal protein and transcription factors
- Disrupts nuclear architecture and proteostasis
-
Transcriptional Dysregulation
- Impaired SAGA complex function
- Decreased histone acetylation
- Downregulation of essential neuronal genes
- Specific vulnerability of photoreceptors and cerebellar Purkinje cells
-
Loss of Normal Function
- Dominant-negative effect on wild-type protein
- Disrupted SAGA-dependent gene expression
- Impaired DNA repair
-
Cellular Stress
- ER stress response activation
- Mitochondrial dysfunction
- Autophagy impairment
- Progressive cerebellar ataxia (gait, limb, oculomotor)
- Retinal degeneration (vision loss, color blindness)
- Slow saccades
- Bulbar dysfunction
- Peripheral neuropathy
- Typical age of onset: 30-40 years (earlier with larger expansions)
SCA7 remains incurable, but several therapeutic approaches are in development:
- ASO-mediated knockdow: Reduce mutant ataxin-7 expression
- AAV gene therapy: Deliver CRISPR components or RNAi
- Allele-specific approaches: Target mutant allele only
- Histone deacetylase (HDAC) inhibitors: Counteract transcriptional repression
- Autophagy enhancers: Promote clearance of mutant protein
- Neuroprotective compounds: Support neuronal survival
- Aggregate breakers: Disrupt protein aggregation
- Physical therapy for ataxia
- Low-vision aids for retinal degeneration
- Speech therapy
- Genetic counseling
¶ Polyglutamine Expansion and Toxicity
Ataxin-7 with expanded polyglutamine (polyQ) tracts causes spinocerebellar ataxia type 7 (SCA7), characterized by:
- Progressive cerebellar degeneration leading to ataxia
- Visual loss due to retinal degeneration
- Slow disease progression over decades
- Anticipation in families (earlier onset in successive generations)
The pathogenic mechanism involves:
- Transcriptional dysregulation: Altered gene expression through aberrant protein interactions
- Proteolytic cleavage: Generation of toxic fragments containing expanded polyQ
- Aggregate formation: Insoluble inclusions in neurons
- Loss of normal function: Disruption of SAGA complex activity
- Oxidative stress: Mitochondrial dysfunction and ROS accumulation
Ataxin-7 is a critical component of the SAGA (Spt-Ada-Gcn5-Acetyltransferase) complex, which regulates:
- Histone acetylation: Modifying chromatin accessibility
- Gene expression: Activating transcription of neuronal genes
- Cellular stress responses: Coordinating adaptive programs
- ** neuronal survival**: Supporting axonal and dendritic maintenance
Mutant ataxin-7 disrupts SAGA function, leading to widespread transcriptional alterations in affected neurons.
Current therapeutic strategies for SCA7 include:
- Gene silencing: ASOs and RNAi targeting mutant ATXN7 allele
- Protein clearance: Enhancing autophagy and UPS-mediated degradation
- Aggregation blockers: Small molecules preventing toxic aggregate formation
- Transcriptional modulators: Restoring SAGA complex function
- Neuroprotective agents: Supporting neuronal survival and function
- Gene replacement: Delivering wild-type ataxin-7 to restore function
- Ataxin-7 aggregates and SCA7 pathogenesis. Brain, 2017.
- SAGA complex dysfunction in SCA7. Human Molecular Genetics, 2015.
- Retinal degeneration in SCA7 mouse models. Neurobiology of Disease, 2018.
- PolyQ expansion mechanisms in SCA7. Cellular and Molecular Life Sciences, 2019.